Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer

Abstract

Regulatory T (Treg) cells are potent suppressors that maintain immune homeostasis. Accumulation of Treg can inhibit effective immune responses in cancer patients, leading to tumor development and progression. Despite direct cytotoxicity, several chemotherapeutic drugs have been reported to deplete Treg cells for better prognosis for cancer patients. Treg cells are a heterogenous population with at least three different subsets, nonsuppressive, resting, and activated Treg cells. However, the characteristics of Treg cell subsets in lung cancer patients and how chemotherapy affects Treg cells remain elusive. In this study, we first analyzed Treg cell subsets in peripheral blood samples from 40 nonsmall cell lung cancer (NSCLC) patients and 20 healthy donors. Treg cells, specifically activated Treg cell subset, significantly increased in patients with NSCLC. Compared to nonsuppressive Treg cells, activated Treg cells expressed higher level of CD39 and predominantly produced inhibitory cytokines. In vitro assay showed that docetaxel reduced all three subsets of Treg cells. More importantly, we found docetaxel-based chemotherapy significantly decreased all three Treg subsets after 4 cycles of treatment in 17 NSCLC patients. Taken together, this study revealed dynamic changes of various Treg cell subsets in NSCLC patients before and after chemotherapy, providing activated Treg cells as a potential target for chemotherapy.

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

“…3,4 Patients with cancer are more susceptible to infection than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treat ments, such as chemotherapy or surgery. [5][6][7][8] Therefore, these patients might be at increased risk of COVID-19 and have a poorer prognosis.…”

Cellular and molecular immunology of lung cancer: therapeutic implications

“…Docetaxel treatment reduced numbers of in vitro Treg cells originally obtained from NSLC patients [89]. In this study, two subsets of Treg cells were found where one Treg subset secreted more IFN-γ and less TGF-β.…”

Immune recognition of irradiated cancer cells

“…Multiple chemotherapeutics including cyclophosphamide, docetaxel, gemcitabine, vinorelbine, and cisplatin have been shown to deplete tumor‐infiltrating T REG cells in vivo, especially when administered according to metronomic regimens . A single dose of cyclophosphamide improved therapeutic responses, delayed time to recurrence, and boosted the establishment of immunological memory in a mouse model of breast cancer co‐treated with RT and the Toll‐like receptor 7 (TLR7) agonist imiquimod .…”